Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Cognitive impairment and seizures are common in our aging population. Anticonvulsant treatment is problematic due to sedation, cognitive slowing, and behavioral changes. Levetiracetam has favorable pharmacokinetics, good efficacy in elderly individuals, a favorable side effect profile, and lacks major drug interactions. We conducted a prospective, uncontrolled, phase 4, open label, 12-week study of levetiracetam to better profile its efficacy, safety, and impact on cognitive/behavioral status in 24 cognitively impaired, elderly individuals. In total, 69% were seizure free for the duration of the study; the remaining participants had satisfactory seizure control. Fatigue was the most common side effect (5 participants). Significant overall improvements were observed for the Folstein’s Mini-Mental State Examination and the Alzheimer’s Disease Assessment Scale—Cognitive. No significant changes were seen in behavioral or functional measures. Levetiracetam is an effective antiepileptic drug in elderly individuals with cognitive impairment. At 3 months, participants who remained on levetiracetam showed excellent cognitive tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 2×
“Nearly 5 million Americans have Alzheimer’s disease, and this is expected to triple by 2050.(1) At this time, 1 in 10 individuals older than 65 and nearly half of those older than 85 have Alzheimer’s disease or a related form of dementia.”
BackgroundGrundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972
Cited by
The cognitive impact of antiepileptic drugs
Eddy, C. M., Rickards, H. E., & Cavanna, A. E. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611417920 · Cited by 404
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183
Sen, A., Akinola, M., Tai, X. Y., Symmonds, M., Davis Jones, G., Mura, S., Galloway, J., Hallam, A., Chan, J. Y. C., Koychev, I., et al. (2021) · Trials · doi:10.1186/s13063-021-05404-4 · Cited by 30
Onos, K. D., Quinney, S. K., Jones, D. R., Masters, A. R., Pandey, R., Keezer, K. J., Biesdorf, C., Metzger, I. F., Meyers, J. A., Peters, J., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12329 · Cited by 16
Metadata
- Authors
- Lippa, C. F., Rosso, A., Hepler, M., Jenssen, S., Pillai, J., & Irwin, D.
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2008-11-10
- Volume
- 25
- Issue
- 2
- Pages
- 149-154
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- OpenAlex
- W2052712624
- Cited by
- 44
- References
- 3
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment. https://app.cochat.ai/papers/10.1177/1533317508325095
- The paper
- Lippa, C. F., Rosso, A., Hepler, M., Jenssen, S., Pillai, J., & Irwin, D. (2010). Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317508325095
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.